drugset
drugset / Trial / NCT06477523

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

NCT06477523 ↗

Phase 1/2 Active not recruiting 57 enrolled Sichuan University
NaSingle-groupOpen-labelTreatment

Summary

Phase Ib/II, open-label, multicentre study to evaluate the efficacy and safety of low-dose radiotherapy (LDRT) combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC.

Timeline

Start
2024-05-16
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody — Intravenous
Subject Carboplatin Small molecule — Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous

Indications

small cell lung carcinoma